Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study
Minseok Albert Kim,1 Heejoon Jang,1 Na Ryung Choi,1 Joon Yeul Nam,1 Yun Bin Lee,1 Eun Ju Cho,1 Jeong-Hoon Lee,1 Su Jong Yu,1 Hyo-Cheol Kim,2 Jin Wook Chung,2 Jung-Hwan Yoon,1 Yoon Jun Kim1 1Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul Nation...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-12-01
|
| Series: | Journal of Hepatocellular Carcinoma |
| Subjects: | |
| Online Access: | https://www.dovepress.com/yttrium-90-radioembolization-is-associated-with-better-clinical-outcom-peer-reviewed-fulltext-article-JHC |
| _version_ | 1818852602375307264 |
|---|---|
| author | Kim MA Jang H Choi NR Nam JY Lee YB Cho EJ Lee JH Yu SJ Kim HC Chung JW Yoon JH Kim YJ |
| author_facet | Kim MA Jang H Choi NR Nam JY Lee YB Cho EJ Lee JH Yu SJ Kim HC Chung JW Yoon JH Kim YJ |
| author_sort | Kim MA |
| collection | DOAJ |
| description | Minseok Albert Kim,1 Heejoon Jang,1 Na Ryung Choi,1 Joon Yeul Nam,1 Yun Bin Lee,1 Eun Ju Cho,1 Jeong-Hoon Lee,1 Su Jong Yu,1 Hyo-Cheol Kim,2 Jin Wook Chung,2 Jung-Hwan Yoon,1 Yoon Jun Kim1 1Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea; 2Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South KoreaCorrespondence: Yoon Jun KimDepartment of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South KoreaTel +82-2-2072-3081Fax +82-2-743-6701Email yoonjun@snu.ac.krBackground: Both trans-arterial radioembolization (TARE) and conventional trans-arterial chemoembolization (TACE) can effectively control hepatocellular carcinoma (HCC) in patients who are not suitable for curative resection. This study compared the effectiveness of TARE and conventional TACE as the initial trans-arterial treatment for hepatocellular carcinoma (HCC) assessed by tumor response and clinical outcomes.Material and Methods: Data were retrospectively analyzed the propensity score-matched cohort for overall survival (OS), progression-free survival (PFS), and intrahepatic PFS in patients who have received TARE or TACE as the first HCC treatment from March 2012 to December 2017.Results: A total of 138 patients initially treated with TARE (n = 54) or TACE (n = 84) was included in this study. Of 138 patients, median age was 59 years and the mean follow-up period was 27.6 months. TARE showed better OS (hazard ratio [HR] = 0.54, 95% confidence interval [CI] = 0.31– 0.92, log-rank P = 0.02), better PFS (HR = 0.51, 95% CI = 0.36– 0.97, log-rank P = 0.04), and better intrahepatic PFS (HR = 0.51, 95% CI = 0.30– 0.88, log-rank P = 0.01) compared with TACE. TARE was an independent prognostic factor for OS (adjusted HR [aHR] = 0.52, 95% CI = 0.30– 0.90, P = 0.02), PFS (aHR = 0.57, 95% CI = 0.35– 0.94, P = 0.03), and intrahepatic PFS (aHR = 0.49, 95% CI = 0.28– 0.84, P = 0.01).Conclusion: TARE as initial trans-arterial treatment is associated with better clinical outcomes such as longer OS compared with TACE in patients with HCC.Keywords: liver neoplasms, brachytherapy, yttrium radioisotopes, embolization |
| first_indexed | 2024-12-19T07:23:32Z |
| format | Article |
| id | doaj.art-1979c4fcf2c1410a84e834eaeb945d57 |
| institution | Directory Open Access Journal |
| issn | 2253-5969 |
| language | English |
| last_indexed | 2024-12-19T07:23:32Z |
| publishDate | 2021-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Hepatocellular Carcinoma |
| spelling | doaj.art-1979c4fcf2c1410a84e834eaeb945d572022-12-21T20:30:52ZengDove Medical PressJournal of Hepatocellular Carcinoma2253-59692021-12-01Volume 81565157771296Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched StudyKim MAJang HChoi NRNam JYLee YBCho EJLee JHYu SJKim HCChung JWYoon JHKim YJMinseok Albert Kim,1 Heejoon Jang,1 Na Ryung Choi,1 Joon Yeul Nam,1 Yun Bin Lee,1 Eun Ju Cho,1 Jeong-Hoon Lee,1 Su Jong Yu,1 Hyo-Cheol Kim,2 Jin Wook Chung,2 Jung-Hwan Yoon,1 Yoon Jun Kim1 1Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea; 2Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South KoreaCorrespondence: Yoon Jun KimDepartment of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South KoreaTel +82-2-2072-3081Fax +82-2-743-6701Email yoonjun@snu.ac.krBackground: Both trans-arterial radioembolization (TARE) and conventional trans-arterial chemoembolization (TACE) can effectively control hepatocellular carcinoma (HCC) in patients who are not suitable for curative resection. This study compared the effectiveness of TARE and conventional TACE as the initial trans-arterial treatment for hepatocellular carcinoma (HCC) assessed by tumor response and clinical outcomes.Material and Methods: Data were retrospectively analyzed the propensity score-matched cohort for overall survival (OS), progression-free survival (PFS), and intrahepatic PFS in patients who have received TARE or TACE as the first HCC treatment from March 2012 to December 2017.Results: A total of 138 patients initially treated with TARE (n = 54) or TACE (n = 84) was included in this study. Of 138 patients, median age was 59 years and the mean follow-up period was 27.6 months. TARE showed better OS (hazard ratio [HR] = 0.54, 95% confidence interval [CI] = 0.31– 0.92, log-rank P = 0.02), better PFS (HR = 0.51, 95% CI = 0.36– 0.97, log-rank P = 0.04), and better intrahepatic PFS (HR = 0.51, 95% CI = 0.30– 0.88, log-rank P = 0.01) compared with TACE. TARE was an independent prognostic factor for OS (adjusted HR [aHR] = 0.52, 95% CI = 0.30– 0.90, P = 0.02), PFS (aHR = 0.57, 95% CI = 0.35– 0.94, P = 0.03), and intrahepatic PFS (aHR = 0.49, 95% CI = 0.28– 0.84, P = 0.01).Conclusion: TARE as initial trans-arterial treatment is associated with better clinical outcomes such as longer OS compared with TACE in patients with HCC.Keywords: liver neoplasms, brachytherapy, yttrium radioisotopes, embolizationhttps://www.dovepress.com/yttrium-90-radioembolization-is-associated-with-better-clinical-outcom-peer-reviewed-fulltext-article-JHCliver neoplasmsbrachytherapyyttrium radioisotopesembolization |
| spellingShingle | Kim MA Jang H Choi NR Nam JY Lee YB Cho EJ Lee JH Yu SJ Kim HC Chung JW Yoon JH Kim YJ Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study Journal of Hepatocellular Carcinoma liver neoplasms brachytherapy yttrium radioisotopes embolization |
| title | Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study |
| title_full | Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study |
| title_fullStr | Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study |
| title_full_unstemmed | Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study |
| title_short | Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study |
| title_sort | yttrium 90 radioembolization is associated with better clinical outcomes in patients with hepatocellular carcinoma compared with conventional chemoembolization a propensity score matched study |
| topic | liver neoplasms brachytherapy yttrium radioisotopes embolization |
| url | https://www.dovepress.com/yttrium-90-radioembolization-is-associated-with-better-clinical-outcom-peer-reviewed-fulltext-article-JHC |
| work_keys_str_mv | AT kimma yttrium90radioembolizationisassociatedwithbetterclinicaloutcomesinpatientswithhepatocellularcarcinomacomparedwithconventionalchemoembolizationapropensityscorematchedstudy AT jangh yttrium90radioembolizationisassociatedwithbetterclinicaloutcomesinpatientswithhepatocellularcarcinomacomparedwithconventionalchemoembolizationapropensityscorematchedstudy AT choinr yttrium90radioembolizationisassociatedwithbetterclinicaloutcomesinpatientswithhepatocellularcarcinomacomparedwithconventionalchemoembolizationapropensityscorematchedstudy AT namjy yttrium90radioembolizationisassociatedwithbetterclinicaloutcomesinpatientswithhepatocellularcarcinomacomparedwithconventionalchemoembolizationapropensityscorematchedstudy AT leeyb yttrium90radioembolizationisassociatedwithbetterclinicaloutcomesinpatientswithhepatocellularcarcinomacomparedwithconventionalchemoembolizationapropensityscorematchedstudy AT choej yttrium90radioembolizationisassociatedwithbetterclinicaloutcomesinpatientswithhepatocellularcarcinomacomparedwithconventionalchemoembolizationapropensityscorematchedstudy AT leejh yttrium90radioembolizationisassociatedwithbetterclinicaloutcomesinpatientswithhepatocellularcarcinomacomparedwithconventionalchemoembolizationapropensityscorematchedstudy AT yusj yttrium90radioembolizationisassociatedwithbetterclinicaloutcomesinpatientswithhepatocellularcarcinomacomparedwithconventionalchemoembolizationapropensityscorematchedstudy AT kimhc yttrium90radioembolizationisassociatedwithbetterclinicaloutcomesinpatientswithhepatocellularcarcinomacomparedwithconventionalchemoembolizationapropensityscorematchedstudy AT chungjw yttrium90radioembolizationisassociatedwithbetterclinicaloutcomesinpatientswithhepatocellularcarcinomacomparedwithconventionalchemoembolizationapropensityscorematchedstudy AT yoonjh yttrium90radioembolizationisassociatedwithbetterclinicaloutcomesinpatientswithhepatocellularcarcinomacomparedwithconventionalchemoembolizationapropensityscorematchedstudy AT kimyj yttrium90radioembolizationisassociatedwithbetterclinicaloutcomesinpatientswithhepatocellularcarcinomacomparedwithconventionalchemoembolizationapropensityscorematchedstudy |